SparingVision to Highlight Progress of its Gene Therapy Programs at ARVO and ASGCT 2025
Paris, 10 April 2025 – SparingVision (“the Company”), a clinical-stage genomic medicine company transforming the treatment of retinal disease, announces that it will present a safety update from the ongoing Phase II PRODYGY trial of its lead product candidate, SPVN06, in retinitis pigmentosa (RP) in a poster at ARVO 2025 (Salt Lake City, Utah, 4–8 May 2025), as well as a safety and preliminary efficacy update from PRODYGY in an oral presentation at the 28th Annual Meeting of the ASGCT (New Orleans, Louisiana, 13–17 May 2025).
At the ASGCT Annual Meeting, the Company will also deliver an oral presentation on its novel analytical method – a triplex digital PCR (dPCR) assay, designed to detect and quantify replicant-competent AAV genomes (rcAAVs) in AAV-based gene therapy products.
Presentation details below:
- Poster Presentation at ARVO, Salt Lake City, Utah, USA
Poster Presentation Title: PRODYGY: A First-in-Human Trial of Rod-Derived Cone Viability Factor (RdCVF) Gene Therapy in Subjects with Rod-Cone Dystrophy
Presenter: Isabelle Audo, M.D.; Ph.D.
Session Title: Retinitis Pigmentosa and IRD I, Number 215
Presentation Number – Posterboard Number: 1442 – A0015
Date and Time: May 5, 2025, 8:30 AM to 10:15 AM Central Time (CT) Room 288-290
- Oral Presentations at ASGCT, New Orleans, USA
Oral Presentation Title: PRODYGY: A First-in-Human Trial of Rod-Derived Cone Viability Factor (RdCVF) Gene Therapy in Subjects with Rod-Cone Dystrophy
Presenter: Daniel Chung, DO, MA
Session Details: Late-Breaking Abstracts I
Date and Time: May 15, 2025, 2:30 PM – 2:45 PM Central Time (CT) Room 288-290
Oral Presentation Title: The Need for an Unbiased Assay to Detect and Quantify Replication Competent AAV in Clinical Vector Products
Presenter: Pierre-Axel Vinot, PharmD; Ph.D.
Session Details: CMC for AAV Vectors
Date and Time: May 16, 2025, 4:00 PM – 4:15 PM Central Time (CT) Room 288-290
NOTES TO EDITORS
Contacts:
Investors: Nathalie Trepo (nathalie.trepo@sparingvision.com)
Media: ICR Healthcare (sparingvision@icrhealthcare.com)
About SparingVision
SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments. Leveraging its unparalleled understanding of retinal diseases, SparingVision has built a compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for inherited retinal diseases (IRDs). Both of its most advanced products, SPVN06 and SPVN20 look to go beyond single gene correction therapies to deliver new mutation agnostic treatments for Retinitis Pigmentosa (RP), a group of IRDs which are a leading cause of blindness globally. The Company also has a strategic collaboration with Intellia Therapeutics (NASDAQ:NTLA) to develop novel genome editing-based treatments for ocular disease utilizing CRISPR-Cas9 technology.
SparingVision is a spin-off from the Paris Vision Institute and backed by high-quality investors including 4BIO Capital, Adbio Partners, Bpifrance, Retinal Degeneration Fund, the venture arm of the Foundation Fighting Blindness, Fondation Voir & Entendre, Intellia Therapeutics, UPMC Enterprises, Jeito Capital and Ysios Capital.
Visit www.sparingvision.com for more and follow us on LinkedIn and X @SparingVision